Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Bristol-Myers Squibb Company



) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.4%. By the end of trading, Bristol-Myers Squibb Company rose $0.58 (1.4%) to $42.24 on light volume. Throughout the day, 6,124,704 shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 8,873,600 shares. The stock ranged in a price between $41.67-$42.34 after having opened the day at $41.76 as compared to the previous trading day's close of $41.66. Other companies within the Drugs industry that increased today were:

GW Pharmaceuticals PLC ADR



), up 17.9%,

Prana Biotechnology



), up 17.5%,




Scroll to Continue

TheStreet Recommends

), up 15.7% and




), up 13.6%.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $68.0 billion and is part of the health care sector. Shares are up 26.8% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates

Bristol-Myers Squibb Company

as a


. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front,

Mast Therapeutics



), down 42.7%,




), down 28.8%,

Ambit Biosciences



), down 10.4% and

Biostar Pharmaceuticals



), down 9.1% , were all laggards within the drugs industry with

Alexion Pharmaceuticals



) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.